Philip Morris International Inc. vs Tilray Brands Inc — how do they compare? Philip Morris International Inc. trades at $200.2 (market cap $312.50B), while Tilray Brands Inc trades at $3.52 (market cap $530.54M). The key difference: Philip Morris International Inc. is far larger — about 589× Tilray Brands Inc's market cap, and Philip Morris International Inc. pays a 3.19% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Philip Morris International Inc. for 85 Days and Tilray Brands Inc for 31 Days on average.
| PM | TLRY | |
|---|---|---|
Market Cap | $312.50B | $530.54M |
Volume | 5,517,172 | 9,099,075 |
Sector | Consumer Staples | Health |
52-Week High | $200.50 | $21.00 |
52-Week Low | $144.33 | $3.57 |
Typical Hold Time | 85 Days | 31 Days |
Enterprise Value | $355.62B | $684.46M |
Dividend Yield | 3.19% | — |
Signals from Pluang's Aura AI — not financial advice
Philip Morris International (PM) trades at $192.69, up 1.2% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 EPS beat expectations at $2.20 vs. $2.05, and revenue growth accelerated to $40.65B in 2025. The company's smoke-free products now drive 42% of revenue, with ZYN and IQOS expansions fueling optimism. Cash flow remains robust, with 2026 operating cash flow projected at $14.3B, supporting dividend growth.
Outlook is positive given earnings momentum and smoke-free transition, but high debt ($42.17B long-term) and regulatory risks persist. The consensus price target of $212.17 implies ~10% upside, though valuation multiples are elevated versus peers. Key risks include FX volatility and slower adoption of next-gen products.
Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.
The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →